Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BMY

Champion - 10+ consecutive years of dividend increases

Max Ratio

11.37

5Y Dividend Growth

46.00 %

Consecutive Years

17 years

5Y Average Payout Ratio

99.15 %
Forward Annual Dividend Yield 6.49 %
Consecutive Years 17
Forward Annual Dividend 3.06 USD
Consistent Years 27
Dividend CAGR 3Y 17.75 %
Continuous Dividends
Dividend CAGR 5Y 7.91 %
Payout Ratio TTM 90.80 %
Dividend CAGR 10Y 5.17 %
Ex Dividend Date 03.07.2025

Bristol-Myers Squibb Company

BMY
Current price
48.06 USD +1.25 USD (+2.67%)
Last closed 46.43 USD
ISIN US1101221083
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 97 805 942 784 USD
Yield for 12 month +13.38 %
1Y
3Y
5Y
10Y
15Y
BMY
21.11.2021 - 28.11.2021

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

57.10 USD

P/E Ratio

17.93

Dividend Yield

6.49 %

Financials BMY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+48 300 000 000 USD

Last Year

+45 006 000 000 USD

Current Quarter

+11 201 000 000 USD

Last Quarter

+12 342 000 000 USD

Current Year

+34 332 000 000 USD

Last Year

+34 313 000 000 USD

Current Quarter

+8 168 000 000 USD

Last Quarter

+7 530 000 000 USD
EBITDA 19 174 000 640 USD
Operating Margin TTM 31.57 %
Price to Earnings 17.93
Return On Assets TTM 7.24 %
PEG Ratio 2.26
Return On Equity TTM 31.99 %
Wall Street Target Price 57.10 USD
Revenue TTM 47 636 000 768 USD
Book Value 8.55 USD
Revenue Per Share TTM
Dividend Share 2.44 USD
Quarterly Revenue Growth YOY -5.60 %
Dividend Yield 6.49 %
Gross Profit TTM 35 578 998 784 USD
Earnings per share 2.68 USD
Diluted Eps TTM 2.68 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -95.90 %
Profit Margin 11.38 %

Stock Valuation BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 17.93
Forward PE 7.00
Enterprise Value Revenue 2.84
Price Sales TTM 2.05
Enterprise Value EBITDA 8.36
Price Book MRQ 5.52

Technical Indicators BMY

For 52 Weeks

39.74 USD 61.84 USD
50 Day MA 47.65 USD
Shares Short Prior Month 37 006 724
200 Day MA 53.98 USD
Short Ratio 2.58
Shares Short 33 614 196
Short Percent 1.65 %